Abstract:Extensive metastasis and frequent relapse are major contributors to the high mortality rate of ovarian cancer (OC) patients. However, the regulation of metastasis and disease recurrence is poorly understood and there is no development of specific treatment strategies to target them. Using an organotypic 3D culture model of the human omentum, we have studied the productive crosstalk between metastasizing OC cells and its microenvironment that is critical for establishment of metastasis. To identify the clinically relevant microRNAs that can regulate both early and advanced metastasis, we combined our 3D omentum culture approach with the end point analysis of microRNA expression profiles of matched primary and metastatic tumors from OC patients. miR-193b was a key microRNA thus identified to be downregulated in early and advanced metastasis. The decrease in miR-193b promoted metastatic colonization by enhancing the ability of the OC cells to invade through the outer layers of the omentum and increased cancer stem cell-like phenotype, helping metastasis initiation. Overexpressing miR-193b resulted in a significant decrease in metastases in OC xenografts while inhibition had the opposite effect. Moreover, treating a chemoresistant OC patient derived xenograft (PDX) model of metastasis with miR-193b significantly reduced metastasis. We have identified the microenvironmental signals and the resulting mechanism of miR-193b downregulation via the ERK/EZH2/DNMT1 axis, using heterotypic coculture models, conditioned medium experiments, secretome analysis, inhibition, and rescue experiments. Basic FGF2 (bFGF2) and IGF binding protein 6 (IGFBP6) were the key mesothelial factors that were responsible for the downregulation of miR-193b in cancer cells. These factors were found to activate ERK in the cancer cells that induced EZH2 and DNMT1 expression. Using ChIP and MeDIP, we discovered that EZH2 induces H3K27me3 in the miR-193b promoter, which helps recruit DMNT1 that catalyzes DNA hypermethylation at the miR-193b promoter. ScRNA-seq analysis of patient metastases confirmed that mesothelial cells are the source of FGF2 and IGFBP6 in the TME. We next proceeded to study the mechanism by which miR-193b decrease promotes metastasis. By performing RNA-seq in OC cells overexpressing miR-193b, we identified cyclin D1 (CCND1) as a key target, which was validated at RNA and protein levels. Knockdown of CCND1 mimicked the decreased expression of stem cells markers (ALDH1A1, OCT4, SOX2 and Nanog), and spheroid formation, caused by miR-193b overexpression. The induction of OC stem cells upon miR-193b inhibition could be rescued by simultaneous overexpression of CCND1. In conclusion, we have identified the mechanism of microenvironment induced downregulation of miR-193b in OC cells that helps establish metastatic tumors by inducing cancer stem cells via its target CCND1. Treating a chemo resistant OC PDX with miR-193b significantly reduced metastases, indicating that miR-193b replacement therapy could be a promising approach to treat OC patients. Citation Format: Subramanyam Dasari, Ji Wang, Frank Cheng, Melissa Halprin, David Pepin, Anirban K. Mitra. Targeting ovarian cancer metastasis initiating cells induced by the microenvironment through ERK/EZH2/DNMT1 mediated miR-193b downregulation [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr A097.

COMMD3-mediated endosomal trafficking of HER2 inhibits the progression of ovarian carcinoma

MiR-5195-3p functions as a tumor suppressor by targeting RHBDD1 in ovarian cancer

HER3/CYLD axis mediates ovarian cancer cell resistance to chemotherapy via upregulation of ABCB1

Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer

METTL3-mediated m6A methylation regulates ovarian cancer progression by recruiting myeloid-derived suppressor cells

CYLD and HER3 Regulate Platinum Resistance in Ovarian Cancer via Drug Efflux Pump ABCB1

HER2 Puzzle Pieces: Non-Coding RNAs as Keys to Mechanisms, Chemoresistance, and Clinical Outcomes in Ovarian Cancer

hsa_circ_0020093 suppresses ovarian cancer progression by modulating LRPPRC activity and miR-107/LATS2 signaling

Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer

CRISPR-Cas9-mediated deletion enhancer of MECOM play a tumor suppressor role in ovarian cancer

Epigenomic Profiling of Epithelial Ovarian Cancer Stem-Cell Differentiation Reveals GPD1 Associated Immune Suppressive Microenvironment and Poor Prognosis

A Positive Feedback Loop of lncRNA DSCR8/miR-98-5p/STAT3/HIF-1α Plays a Role in the Progression of Ovarian Cancer

Exploring tumor microenvironment in molecular subtyping and prognostic signatures in ovarian cancer and identification of SH2D1A as a key regulator of ovarian cancer carcinogenesis

Tripartite-motif 3 represses ovarian cancer progression by downregulating lactate dehydrogenase A and inhibiting AKT signaling

Extracellular vesicle loaded with miR-494-3p can suppress ovarian cancer cell

EZH2 Mediated Metabolic Rewiring Promotes Tumor Growth Independently of Histone Methyltransferase Activity in Ovarian Cancer.

CircUBE2D2 regulates HMGB1 through miR-885-5p to promote ovarian cancer malignancy

Abstract A097: Targeting ovarian cancer metastasis initiating cells induced by the microenvironment through ERK/EZH2/DNMT1 mediated miR-193b downregulation

NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma

COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma

Significance of dysregulated M2 macrophage and ESR2 in the ovarian metastasis of gastric cancer